Tricida Analyst & Investor Event

New York City, October 15, 2019

Please join Tricida for a comprehensive look at the company’s late stage drug candidate, veverimer, a potential first-in-class treatment for metabolic acidosis in patients with chronic kidney disease (CKD).  Metabolic acidosis is a condition that afflicts approximately 3 million adults in the US alone and can lead to muscle wasting, bone loss and progression of CKD.

Date:
Tuesday, October 15

Time:
8:00am - 11:30am

Location:
St. Regis Hotel
Two East 55th St, New York City

For more information or to RSVP, contact InvestorDay@tricida.com

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Tricida, Inc. [TCDA] US$1,742 MM MCap
Tri­ci­da is a late-stage phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of their drug can­di­date, TR­C101, a non-ab­sorbed po­ly­mer de­signed to treat metabolic aci­do­sis by bind­ing and re­mov­ing acid from the gas­troin­testi­nal tract, or GI tract. [more in­for­ma­tion]